Biotech firm files bankruptcy w $115M debt; Eli Lilly, Astellas bet on it anyway
randycuperti
·
2026-06-27
·
via HN's home page
 | |
Lilly is paying $50 million as a "stalking horse" for Sangamo Therapeutics capsid delivery program, "zinc finger" gene-editing and modular integrase platforms and brain disease treatment. Astellas is paying $50 million for the Fabry disease late-stage gene therapy program. |
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。